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Introduction: Pulmonary amyloidosis is rare and is often misdiagnosed due a lack of general awareness.
Case presentation: In this case report we describe a 69-year-old Chinese woman who presented with a right lower
lobe pulmonary nodule. After video-assisted thoracoscopic lobectomy, a histopathologic diagnosis of pulmonary
nodular amyloidosis was rendered. She has done well postoperatively, showing no local recurrence or distal disease
in an 8-month follow-up period.
Conclusions: Distinguishing parenchymal nodular amyloidosis from a malignant lung tumor is often quite difficult.
In the differential diagnosis of pulmonary nodules, nodular amyloidosis should be considered to avoid unnecessary
lobectomy.
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Amyloidosis is an uncommon disease whereby insoluble
proteinaceous amyloid fibrils are deposited in bodily tis-
sues. Only eight patients per million per year are af-
fected. Localized pulmonary amyloidosis is an even less
likely occurrence, incorporating vague clinical features
and limited treatment options. Here we report the case a
69-year old woman with a pulmonary nodule of her
right lower lobe that was suspicious of lung carcinoma.
Ultimately, localized pulmonary amyloidosis was con-
firmed following video-assisted thoracoscopic (VAT)
lobectomy.
Case presentation
A 69-year-old Chinese woman was admitted for cough
and expectoration (yellow phlegm) of about 2 weeks’
duration. These symptoms developed without apparent
cause and in the absence of other problems, such as
chest pain and/or distress, breathlessness, fever,
hemoptysis, nausea, or vomiting. A computed tomog-
raphy (CT) scan of her chest showed a rough-edged
shadow nearly 24×18×30mm in the right lower lobe of
her lung (Figure 1). She acknowledged several chronic
disorders, including a 20-year history of bronchitis,* Correspondence: huntercj2004@yahoo.com
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reproduction in any medium, provided the orrecurrent urinary tract infections for 4 years, and abnor-
mal pretibial skin pigmentation of 10-year duration in-
volving both lower limbs. She denied smoking and had
no family history of lung cancer. A review of her systems
was noncontributory. The results of a peripheral blood
count, baseline serum chemistry screening, and urinalysis
were normal on admission, as were tumor biomarker tests
and a purified protein derivative test for tuberculosis. A
rough-edged shadow of her right lower lobe was again
seen on an enhanced CT scan of her chest, although a CT
scan of her abdomen, magnetic resonance imaging of her
brain, and a bone scan were all normal. Her right bron-
chial tree also appeared normal on bronchoscopic exam-
ination, with no indication of malignancy in the biopsy
and washings procured.
A right-sided video-assisted thoracoscopic (VAT)
lower lobectomy and systematic mediastinal lymphade-
nectomy were performed. A tumor of her right lower
lobe, roughly 3cm in diameter, was evident at surgery,
with puckering of visceral pleura. Histopathologic exam-
ination later confirmed a diagnosis of nodular amyloid-
osis, supported by Congo red- and methyl violet-positive
staining (Figure 2A-C). Bronchial and mediastinal lymph
nodes were interpreted as reactive hyperplasia.This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Computed tomography scans of chest: A, B) tumor-like mass with blurred contour and irregular margin shown in lung and
mediastinal windows.
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charged 4 days after surgery and showed no signs of
local recurrence or distal disease at an 8-month follow-
up visit.
Discussion
Amyloidosis, first described by Virchow in 1854, encom-
passes a spectrum of clinical conditions with differing
manifestations where abnormal extracellular deposition
of amyloid is common [1]. Formerly grouped by etiology
(primary versus secondary), it is now classified as either
systemic or limited forms. Systemic disease typically is
seen in patients suffering chronic suppuration, myeloma,
or tuberculosis and may affect multiple organs (withFigure 2 Histopathology (×200): A) routine hematoxylin and eosin sta
(purple) stains, positive for amyloid.exception of the brain) but is less apt to involve the
lungs. However, the respiratory tract (that is, lungs and
blood vessels) is commonly affected in localized dis-
ease. The published incidence of amyloidosis is eight
patients per million per year [2]. A total of 89 patients
were diagnosed with amyloidosis at Beijing Union
Medical College Hospital between 1986 and 2005, 59
of whom had respiratory tract involvement [3].
Amyloidosis of the respiratory tract is subsequently
divided into laryngeal, tracheobronchial, and parenchy-
mal types, as noted by Gillmore and Hawkins [4]. Par-
enchymal disease is then further categorized as focal
(nodular) or diffuse (interstitial). The patient reported
here qualifies as parenchymal nodular amyloidosisin of amyloid nodule; B, C) Congo red (pink) and methyl violet
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as amyloid tumor for obvious reasons. Pulmonary
amyloid nodules may occur singly or as multiple le-
sions that tend to occupy peripheral and subpleural
areas of lower lobes [4]. This particular nodule was in-
deed found in the periphery of her right lower lobe.
Such lesions are occasionally discovered by imaging or
tissue biopsy and are usually asymptomatic.
According to the literature, parenchymal nodular
amyloidosis is not linked with systemic disease but
may persist for years, running a benign course (with
reticulonodular pattern) [5]. On CT scan of the chest,
four features are in favor of amyloid nodule: 1) sharp
edges and lobulated contours; 2) calcifications (ap-
proximately 50%); 3) variability in shape and size (0.5
to 15cm); and 4) slow, non-regressive growth, rarely
with cavitation [4,6]. However, none of these are spe-
cific for the disease.
Many of the above factors were in keeping with our
patient. Although hospitalized for respiratory symp-
toms (cough, expectoration), chronic bronchitis, rather
than the demonstrable amyloid nodule, may explain
these complaints. It is difficult to diagnose these
lesions, owing to their diverse clinical presentations
and lack of definitive imaging properties. The imaging
similarities with malignant lung tumors make differen-
tiation especially difficult. A positron emission tomog-
raphy (PET)-CT scan may help in distinguishing the
two, given that amyloidosis for the most part is not
fluorodeoxyglucose-avid. However, a negative result
would not necessarily secure a diagnosis of amyloid-
osis, and PET-CT scans are costly. Routine fiberoptic
bronchoscopy has a low diagnostic accuracy, but CT-
guided percutaneous lung biopsy or transbronchial biopsy
may afford better success in establishing a diagnosis [7].
Currently, the gold standard is histopathologic confirm-
ation, marked by green birefringence of Congo red-
stained tissue under cross-polarization [8].
In this instance, bronchoscopic washings and biopsy
disclosed only chronic inflammation, and a CT-guided
biopsy was refused by the patient due to the high risk
of complications. The diagnosis of pulmonary nodular
amyloidosis was ultimately achieved after VAT lobec-
tomy, performed without intraoperative frozen section
for two primary reasons: 1) puckering of visceral
pleura was interpreted as a manifestation of malig-
nancy, and 2) wide local excision would have proved
challenging, given the location of the nodule (deep and
close to hilar region).
Because pulmonary nodular amyloidosis is so un-
common, no randomized controlled trials are available
for therapeutic insight. By consensus, however, asymp-
tomatic patients may not require surgical intervention.
Periodic follow-up with careful monitoring mayinstead suffice. For symptomatic patients, carbon dio-
xide laser ablation or surgery (bronchoscopic or open
resection) may be used as warranted [9], although re-
lapse is still possible [4]. In the past, low-dose external
beam radiation has also conferred some benefit [10].
Regardless of the therapy chosen, we feel that close
clinical vigilance is paramount in managing this
disease.
Conclusion
Distinguishing parenchymal nodular amyloidosis from
malignant lung tumors is difficult due to imaging simi-
larities. Although rare, pulmonary amyloidosis must be
kept in mind, opting for intraoperative diagnosis if feas-
ible to avoid unnecessary lobectomy.
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